Nov 5, 4:02 PM ET
TransMedics reported third-quarter 2026 revenue of $203.0 million, up 41%, and raised its full-year 2026 revenue guidance to $764-$774 million, including about $14 million from PAD Aviation. Net income fell to $17.1 million, or $0.46 per diluted share, from $24.3 million, or $0.66, a year earlier, as operating expenses rose to $90.5 million.
- Q3 2026 revenue was $203.0 million, up from $143.8 million in Q3 2025.
- Q3 2026 net income was $17.1 million, or $0.46 per diluted share, versus $24.3 million, or $0.66, in Q3 2025.
- Full-year 2026 revenue guidance was raised to $764-$774 million, including PAD Aviation; excluding PAD Aviation, guidance is $750-$760 million, up from $737-$757 million.
- Operating expenses were $90.5 million, compared with $61.3 million in Q3 2025; cash was $493.0 million as of September 30, 2026.
Read the filing on SEC.gov ↗
Sep 10, 4:40 PM ET
TransMedics appointed Fernando Araujo, most recently CFO of GE HealthCare's Advanced Imaging Solutions segment, as Chief Financial Officer and Treasurer effective September 21, 2026, succeeding Gerardo Hernandez, who will move to a non-executive role and then a senior advisor position focused on Latin America. In the same announcement, the company reiterated its 2026 revenue guidance of $737 million to $757 million, which excludes PAD Aviation and will be revisited with third quarter results. The filing reports no change to financial results or guidance, but the change in finance leadership is a notable item for shareholders.
- Fernando Araujo, age 46, becomes CFO and Treasurer effective September 21, 2026, with a $590,000 base salary and a 60% target bonus
- Araujo receives a $200,000 cash sign-on bonus plus initial stock option and RSU awards each with a grant date value of approximately $1.75 million
- Gerardo Hernandez remains a non-executive employee through December 31, 2026, then serves as a non-employee senior advisor until April 30, 2027
- 2026 revenue guidance of $737 million to $757 million was reiterated; the company will revisit it with third quarter 2026 results
Read the filing on SEC.gov ↗
Aug 4, 4:05 PM ET
TransMedics reported second quarter 2026 revenue of $189.9 million, up 21% from a year earlier. Income from operations fell to $23.7 million from $36.6 million, and diluted earnings per share fell to $0.41 from $0.92, as operating expenses rose to $89.5 million from $60.0 million. The company raised the low end of its full-year 2026 revenue guidance to a range of $737 million to $757 million, which excludes PAD Aviation.
- Q2 2026 revenue was $189.9 million, up 21% from $157.4 million; product revenue was $111.2 million and service revenue was $78.8 million.
- Income from operations was $23.7 million versus $36.6 million, and diluted EPS was $0.41 versus $0.92 in Q2 2025.
- Full-year 2026 revenue guidance low end raised; range is now $737 million to $757 million, up from $727 million to $757 million.
- Operating expenses were $89.5 million, driven by planned investment in OCS Kidney, Gen 3.0 and clinical programs; cash was $472.7 million as of June 30, 2026.
Read the filing on SEC.gov ↗
May 5, 4:05 PM ET
TransMedics reported first quarter 2026 revenue of $173.9 million, up 21% from a year earlier, but net income fell to $7.3 million, or $0.20 per diluted share, from $25.7 million, or $0.70 per share, in the first quarter of 2025. The company reiterated its full year 2026 revenue guidance of $727 million to $757 million, which it said represents 20% to 25% growth.
- Revenue of $173.9 million for the quarter ended March 31, 2026, up 21% from $143.5 million a year earlier
- Net income of $7.3 million, or $0.20 per diluted share, versus $25.7 million, or $0.70, in the prior-year quarter; gross margin was 58% compared with 61%
- Adjusted net income of $10.9 million, or $0.30 per diluted share, a non-GAAP measure; cash was $461.7 million as of March 31, 2026
- Full year 2026 revenue guidance of $727 million to $757 million was reiterated, not changed
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.